ReviewIrish journal of medical science2023
Toxoplasma gondii vaccine candidates: a concise review.
Review in Irish journal of medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Global prevalence of Neospora caninum in rodents: A systematic review and meta-analysis.Veterinary medicine and science · 2023Pooled it
- Systematic Review and Meta-analysis of Role of Felids as Intermediate Hosts in the Life Cycle of Neospora caninum Based on Serological Data.Acta parasitologica · 2023Pooled it
- A Live Attenuated AP2X-1-DeficientAnimals : an open access journal from MDPI · 2026Article
- An Immunoinformatic Approach for a Multi-Epitope Vaccine Against Toxoplasma gondii.Parasite immunology · 2026Article
- Protective Effect Against Acute Experimental Toxoplasmosis Conferred by Intranasal Immunisation withVaccines · 2026Article
- Development of a SAG1-based colloidal gold immunochromatographic strip for rapid serological detection of swine Toxoplasma gondii.Parasites & vectors · 2026Article
- Advances and Translational Challenges inVeterinary sciences · 2026Review
- Nanoparticle-Based Vaccines Against Toxoplasma gondii: Immunological Rationale, Platform Strategies, and Translational Challenges.Transboundary and emerging diseases · 2026Review
- Development and Evaluation of Six Novel Recombinant GRA Proteins in Serodiagnosis of Human Toxoplasmosis.Current issues in molecular biology · 2025Article
- Design and immunological evaluation of a multi-epitope vaccine candidate againstFood and waterborne parasitology · 2025Article
- Research on inner membrane complex protein 1: a novel nanovaccines against Toxoplasma gondii.BMC veterinary research · 2025Article
- Anti-Antioxidants (Basel, Switzerland) · 2025Article
- PLGA nanoparticles as an efficient carrier inFrontiers in immunology · 2025Article
- In silico identification and ex vivo evaluation of Toxoplasma gondii peptides restricted to HLA-A*02, HLA-A*24 and HLA-B*35 alleles in human PBMC from a Colombian population.Medical microbiology and immunology · 2024Article
- TgVax452, an epitope-based candidate vaccine targeting Toxoplasma gondii tachyzoite-specific SAG1-related sequence (SRS) proteins: immunoinformatics, structural simulations and experimental evidence-based approaches.BMC infectious diseases · 2024Article
- Single Cell Expression Systems for the Production of Recombinant Proteins for Immunodiagnosis and Immunoprophylaxis of Toxoplasmosis.Microorganisms · 2024Review
- Maltodextrin-Nanoparticles as a Delivery System for Nasal Vaccines: A Review Article.Pharmaceutics · 2024Review
- A novel mRNA vaccine, TGGT1_278620 mRNA-LNP, prolongs the survival time in BALB/c mice with acute toxoplasmosis.Microbiology spectrum · 2024Article
- Serological and molecular detection of Toxoplasma gondii and Neospora caninum in free-ranging rats from Nagpur, India.Parasitology research · 2023Article
- Manipulative neuroparasites: uncovering the intricacies of neurological host control.Archives of microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis. It has been shown that the severity of symptoms depends on the functioning of the host immune system. Although T. gondii infection typically does not lead to severe disease in healthy people and after infection, it induces a stable immunity, but it can contribute to severe and even lethal Toxoplasmosis in immunocompromised individuals (AIDS, bone marrow transplant and neoplasia). The antigens that have been proposed to be used in vaccine candidate in various studies include surface antigens and secretory excretions that have been synthesized and evaluated in different studies. In some studies, secretory antigens play an important role in stimulating the host immune response. Various antigens such as SAG, GRA, ROP, ROM, and MAG have been from different strains of T. gondii have been synthesized and their protective effects have been evaluated in animal models in different vaccine platforms including recombinant antigens, nanoparticles, and DNA vaccine. Four bibliographic databases including Science Direct, PubMed Central (PMC), Scopus, and Google Scholar were searched for articles published up to 2020.The current review article focuses on recent studies on the use and usefulness of recombinant antigens, nanoparticles, and DNA vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.